The pharmaceutical microbiology testing service at Aurigene is supported by BSL-2 compliant lab and a dedicated in vivo facility for bacterial and fungal infection murine disease models. Our team has collaborated on numerous anti-bacterial and anti-fungal agent discovery projects with innovator pharma companies. We have a dedicated team of scientists and allied staff with vast experience in anti-infective drug discovery projects. We have established in vitro assays and in vivo murine efficacy models.
We also support generic product filings through bioequivalance studies of in vitro time-kill kinetics against reference drug.
In vitro Pharmaceutical Microbiology Testing Services
- Pharmacodynamic studies: Drug-organism interaction
- MIC and MBC: Susceptibility indicators; major parameters used to quantify the activity of an antibacterial agent against the target pathogen
- Time kill kinetics: Information on the time course and rate of antimicrobial activity
- PAE and PA-SME: Information on persistent effects of antibacterial agents
- Others: Antimicrobial combination/effect of serum proteins on MIC/ biofilm studies
In vivo Pharmaceutical Microbiology Testing Services
- Systemic infection models: Acute lethal model to generate POC and determine ED50 - primary screening
- Respiratory tract infection models: Test efficacy of NCEs in highly vascularized tissue like lungs
- Thigh infection models: Test efficacy of NCEs in poorly vascularized tissues like thighs
- Urinary tract infection models: Testability of NCEs to clear UTIs
- Organ burden models: Testability of NCEs to clear the disseminated infection
Why Aurigene Microbiology Testing Services?
Submissions to the US FDA
Highly qualified & experienced scientists
Audited by the US FDA with Zero 483 in 2019
BSL-2 compliant microbiology lab
Wide range of infectious models & microbiology assay capabilities
Other Services
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Microbiology Testing
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Learning Resources
Neoantigen Specific T cells For Cancer Immunotherapy
An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...
Read More
Evolution in Pharma Industry and Demand for Integrated CDMO
The pharma industry is evolving and a demand for integrated CDMOs, which can help accelerating innovations, is part of the evolution....
Read More
Physiochemical Characterization Services
Backed by our strong chemistry, we enable “Finger-print” protein structure and functional characterization for proteins from naked proteins to hyperglycosylated or derivatized proteins. ...
Read More
Fixed Dose Combination Formulation
Introduction: A fixed dose combination (FDC) includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. Fixed dose combination (FDC) product is expected to provide below advantages: Improved medication compliance by reducing the pill burden of patients. To achieve synergistic activity If combinations include doses of each drug...
Read More
Synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3- dihydroquinazolin-4(1H)-one via molybdenum hexacarbonyl mediated CO gas- and ligand free carbonylative reactions
2016
Carbon monoxide gas and ligand-free conditions were developed for the synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3-dihydroquinazolin4(1H)-one via catalytic carbonylation with molybdenum hexacarbonyl as an efficient carbonylating agent for the three-component reaction of isatoic anhydride, amine, iodobenzene. Mo(CO)6 is a solid carbon monoxide source. The quinazoli...
Read More-
Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More -
Development of novel paullone-based PROTACs as anticancer agents
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More -
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation
Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market